IL15 and cancer: Phase I and II clinical trials of haNK, alone, or in combination with anti-PD-L1 Ab (avelumab), a cancer vaccine, or super-IL-15, are ongoing for the treatment of triple negative breast cancer, squamous cell carcinoma, Merkel cell carcinoma, pancreatic cancer, and other types of cancers (NCT03027128, NCT03387085, NCT03387111, NCT03853317, and NCT03586869).